Cargando…

Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo

BACKGROUND: There is growing interest in soluble biomarkers that could be used on the group level for screening purposes in small proof of principle studies during early drug development. We investigated early changes in serum levels of several candidate biomarkers involved in cartilage and bone met...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Kuijk, Arno W. R., DeGroot, Jeroen, Koeman, Rishma C., Sakkee, Nico, Baeten, Dominique L., Gerlag, Danielle M., Tak, Paul P.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937309/ https://www.ncbi.nlm.nih.gov/pubmed/20844595 http://dx.doi.org/10.1371/journal.pone.0012556

Ejemplares similares

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
por: van Kuijk, A W R, et al.
Publicado: (2008)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
por: Bolt, Janne W., et al.
Publicado: (2022)

Synovitis in Psoriatic Arthritis: Immunohistochemistry, Comparisons With Rheumatoid Arthritis, and Effects of Therapy
por: van Kuijk, Arno W. R., et al.
Publicado: (2011)

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment
por: Lebre, Maria C, et al.
Publicado: (2012)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
por: Noordenbos, Troy, et al.
Publicado: (2011)

Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice
por: van Mens, Leonieke J. J., et al.
Publicado: (2017)

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2019)

Serum biomarkers to predict clinical response in proof-of-concept trials in spondyloarthritis
por: Turina, Maureen, et al.
Publicado: (2011)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2020)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019)

Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment()()
por: Garcia-Souto, Fernando
Publicado: (2021)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study
por: Hunter, David J, et al.
Publicado: (2007)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis
por: Tang, Man W., et al.
Publicado: (2017)

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
por: Paramarta, Jacqueline E, et al.
Publicado: (2014)

Serum cartilage oligomer proteins in psoriatic arthritis
por: Ujfalussy, I, et al.
Publicado: (2003)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
por: Landewé, Robert, et al.
Publicado: (2019)

Brain abscess in a patient with psoriatic arthritis treated with adalimumab: A case report
por: Lo, Yu-Pei, et al.
Publicado: (2020)

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2020)

The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis – preliminary report
por: Krawczyk, Agata, et al.
Publicado: (2021)

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
por: Wijbrandts, C A, et al.
Publicado: (2008)

Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab
por: Smith, Karen, et al.
Publicado: (2018)

Proof-of-Concept Double-Blind Placebo-Controlled Trial Measuring Cartilage Composition in Early Rheumatoid Arthritis under TNF-α-Inhibitor Therapy
por: Frenken, Miriam, et al.
Publicado: (2023)

Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
por: Teoli, M., et al.
Publicado: (2012)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

Superimposed Effects of Adalimumab and Linagliptin on the Development of Bullous Pemphigoid in a Psoriatic Patient: A Case Report
por: Yamada, Katsuhiro, et al.
Publicado: (2021)

Distinct synovial immunopathology in Behçet disease and psoriatic arthritis
por: Cañete, Juan D, et al.
Publicado: (2009)

Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling Markers in Women with Rheumatoid Arthritis
por: Szeremeta, Anna, et al.
Publicado: (2023)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
por: Behrens, Frank, et al.
Publicado: (2018)

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

The Assessment of Selected Bone and Cartilage Biomarkers in Psoriatic Patients from Poland
por: Bartosińska, Joanna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nue30ifmk4p8jftbqnogf02n2h